179 related articles for article (PubMed ID: 19908923)
21. Is the societal approach wide enough to include relatives? Incorporating relatives' costs and effects in a cost-effectiveness analysis.
Davidson T; Levin LA
Appl Health Econ Health Policy; 2010; 8(1):25-35. PubMed ID: 20038191
[TBL] [Abstract][Full Text] [Related]
22. Equity-efficiency trade-offs in health technology assessment.
Williams AH; Cookson RA
Int J Technol Assess Health Care; 2006; 22(1):1-9. PubMed ID: 16673674
[TBL] [Abstract][Full Text] [Related]
23. What is the value of treating schizophrenia?
Carr VJ; Lewin TJ; Neil AL
Aust N Z J Psychiatry; 2006; 40(11-12):963-71. PubMed ID: 17054564
[TBL] [Abstract][Full Text] [Related]
24. Estimating sign-dependent societal preferences for quality of life.
Attema AE; Brouwer WB; l'Haridon O; Pinto JL
J Health Econ; 2015 Sep; 43():229-43. PubMed ID: 26263893
[TBL] [Abstract][Full Text] [Related]
25. Inclusion of equity in economic analyses of public health policies: systematic review and future directions.
Lal A; Moodie M; Peeters A; Carter R
Aust N Z J Public Health; 2018 Apr; 42(2):207-213. PubMed ID: 28898490
[TBL] [Abstract][Full Text] [Related]
26. A cost-based equity weight for use in the economic evaluation of primary health care interventions: case study of the Australian Indigenous population.
Ong KS; Kelaher M; Anderson I; Carter R
Int J Equity Health; 2009 Oct; 8():34. PubMed ID: 19807930
[TBL] [Abstract][Full Text] [Related]
27. Incorporating societal concerns for fairness in numerical valuations of health programmes.
Nord E; Pinto JL; Richardson J; Menzel P; Ubel P
Health Econ; 1999 Feb; 8(1):25-39. PubMed ID: 10082141
[TBL] [Abstract][Full Text] [Related]
28. An equity framework for health technology assessments.
Culyer AJ; Bombard Y
Med Decis Making; 2012; 32(3):428-41. PubMed ID: 22065143
[TBL] [Abstract][Full Text] [Related]
29. Equity in HTA: what doesn't get measured, gets marginalised.
Cookson R; Mirelman AJ
Isr J Health Policy Res; 2017; 6():38. PubMed ID: 28694961
[TBL] [Abstract][Full Text] [Related]
30. Income-based equity weights in healthcare planning and policy.
Herlitz A
J Med Ethics; 2017 Aug; 43(8):510-514. PubMed ID: 27986799
[TBL] [Abstract][Full Text] [Related]
31. The Corrective Approach: Policy Implications of Recent Developments in QALY Measurement Based on Prospect Theory.
Lipman SA; Brouwer WBF; Attema AE
Value Health; 2019 Jul; 22(7):816-821. PubMed ID: 31277829
[TBL] [Abstract][Full Text] [Related]
32. Comparative analysis of decision maker preferences for equity/efficiency attributes in reimbursement decisions in three European countries.
Baji P; García-Goñi M; Gulácsi L; Mentzakis E; Paolucci F
Eur J Health Econ; 2016 Sep; 17(7):791-9. PubMed ID: 26296623
[TBL] [Abstract][Full Text] [Related]
33. Do the equity-efficiency preferences of the Israeli Basket Committee match those of Israeli health policy makers?
Shmueli A
Isr J Health Policy Res; 2017; 6():20. PubMed ID: 28469840
[TBL] [Abstract][Full Text] [Related]
34. Cost-Value Analysis and the SAVE: A Work in Progress, But an Option for Localised Decision Making?
Karnon J; Partington A
Pharmacoeconomics; 2015 Dec; 33(12):1281-8. PubMed ID: 26100285
[TBL] [Abstract][Full Text] [Related]
35. Health policy approaches to measuring and valuing human life: conceptual and ethical issues.
Morrow RH; Bryant JH
Am J Public Health; 1995 Oct; 85(10):1356-60. PubMed ID: 7573617
[TBL] [Abstract][Full Text] [Related]
36. Health utility indices and equity considerations.
Bleichrodt H
J Health Econ; 1997 Feb; 16(1):65-91. PubMed ID: 10167345
[TBL] [Abstract][Full Text] [Related]
37. Methods and issues associated with the use of quality-adjusted life-years.
Revicki DA; Lenderking WR
Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):105-14. PubMed ID: 22280200
[TBL] [Abstract][Full Text] [Related]
38. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
39. Integrating Alternative Social Value Judgments Into Cost-Effectiveness Analysis of Vaccines: An Application to Varicella-Zoster Virus Vaccination.
Luyten J; van Hoek AJ
Value Health; 2021 Jan; 24(1):41-49. PubMed ID: 33431152
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
